Fair Value Measurements (Details) (USD $) In Thousands, unless otherwise specified	6 Months Ended	9 Months Ended	12 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended									9 Months Ended		3 Months Ended
	Jun. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Sep. 30, 2013 Auction Rate Securities [Member]	Sep. 30, 2012 Auction Rate Securities [Member]	Sep. 30, 2013 Auction Rate Securities [Member]	Sep. 30, 2012 Auction Rate Securities [Member]	Dec. 31, 2012 Auction Rate Securities [Member]	Sep. 30, 2013 Auction Rate Securities [Member] Minimum [Member]	Dec. 31, 2012 Auction Rate Securities [Member] Minimum [Member]	Sep. 30, 2013 Auction Rate Securities [Member] Maximum [Member]	Dec. 31, 2012 Auction Rate Securities [Member] Maximum [Member]	Sep. 30, 2013 Auction Rate Securities [Member] Weighted average [Member]	Dec. 31, 2012 Auction Rate Securities [Member] Weighted average [Member]	Sep. 30, 2013 Azedra commercialization [Member]	Sep. 30, 2013 MIP - 1404 commercialization [Member]	Sep. 30, 2013 Small molecule therapeutics commercialization [Member]	Sep. 30, 2013 Net sales targets [Member]	Sep. 30, 2013 Net sales targets [Member] Minimum [Member]	Sep. 30, 2013 Net sales targets [Member] Maximum [Member]	Sep. 30, 2013 Net sales targets [Member] Weighted average [Member]	Sep. 30, 2013 Contingent Consideration Liability [Member]	Sep. 30, 2012 Contingent Consideration Liability [Member]	Sep. 30, 2013 Contingent Consideration Liability [Member]	Sep. 30, 2012 Contingent Consideration Liability [Member]	Sep. 30, 2013 Contingent Consideration Liability [Member] Minimum [Member]	Sep. 30, 2013 Contingent Consideration Liability [Member] Maximum [Member]	Sep. 30, 2013 U.S. Government Subsidized Securities [Member]	Sep. 30, 2013 Recurring [Member]	Dec. 31, 2012 Recurring [Member]	Sep. 30, 2013 Recurring [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	Dec. 31, 2012 Recurring [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	Sep. 30, 2013 Recurring [Member] Significant Other Observable Inputs (Level 2) [Member]	Dec. 31, 2012 Recurring [Member] Significant Other Observable Inputs (Level 2) [Member]	Sep. 30, 2013 Recurring [Member] Significant Unobservable Inputs (Level 3) [Member]	Dec. 31, 2012 Recurring [Member] Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Entity Acquisition, Contingent Consideration, at Fair Value		$ 15,900	$ 0	$ 0																										$ 15,900		$ 0		$ 0		$ 15,900
Money Market Funds		70,355																												70,355	56,224	70,355	56,224	0	0	0	0
Auction Rate Securities	2,208	2,208	3,240																										2,208	2,208	3,240	0	0	0	0	2,208	3,240
Asset, total																														72,563	59,464	70,355	56,224	0	0	2,208	3,240
Liability, total																														15,900		0		0		15,900
Maturity period of US government subsidized securities (in years)		10 years
Duration of securities subject to temporary impairment, minimum (in months)		12 months
Amount of temporary impairment	192		260
Summary of activities in financial instruments with significant Level 3 inputs [Roll Forward]
Balance at beginning of period					2,208	3,240	3,240	3,332	3,332														15,900	0	0	0
Transfers into Level 3					0	0	0	0
Transfers out of Level 3					0	0	0	0
Total gains (losses)
Included in net loss					0	0	0	0
Included in other comprehensive loss					0	0	68	8
Settlements at par					0	0	(1,100)	(100)
Fair value of contingent consideration - acquisition of Molecular Insight																							0	0	15,900	0
Fair value adjustment to contingent consideration included in net loss																							0	0	0	0
Balance at end of period					2,208	3,240	2,208	3,240	3,240														15,900	0	15,900	0
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for assets or liabilities held at the end of the reporting period					0	0	0	0															0	0	0	0
Fair Value Measurements, Quantitative Information
Period of milestone expected achievement																2016	2017	2020		2018	2022
Fair Value					$ 2,208		$ 2,208		$ 3,240							$ 2,300	$ 2,000	$ 500	$ 11,100
Valuation technique					Discounted cash flow model				Discounted cash flow model							Probability adjusted discounted cash flow model	Probability adjusted discounted cash flow model	Probability adjusted discounted cash flow model	Monte-Carlo simulation
Redemption period										5 years	4 years	15 years	15 years	6 years	5 years 10 months 24 days
Discount Rate										0.375%	0.125%	2.031%	2.102%	1.23%	0.71%	10.00%	10.00%	10.00%	12.50%								10.00%	12.50%
Probability of success																40.00%	31.00%	19.00%		19.00%	40.00%	32.90%